Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8252W HIGH $5.19
Volume
710.64 K
Value Traded
596.94 K
Short % Float
3.65%
Days to Cover
6.9
-8.74%Week
-35.16%1 Month
-57.65%3 Month
-54.4%6 Month
-97.58%5 Year
-88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
96.28 M
EPS (TTM)
-0.44
P/E Ratio
-
Ent. Value
-3.55 M
Total Shares
116.00 M
Float Shares
98.05 M
Insiders
15.47%
Institutions
19.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NBP Catalyst Timeline
Dated clinical, regulatory and corporate events for NovaBridge Biosciences
Catalyst Timeline
Dated clinical, regulatory & corporate events for NovaBridge Biosciences
411Total events
19Upcoming
106Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Poster PresentationGivastomigPresentation
Updated Phase 1b results presented at ESMO Congress 2026
HER2-negative first-line metastatic gastroesophageal adenocarcinomasource ↗
▲Full ResultsGivastomigClinical Data
Mature Phase 1b dataset with nearly 18 months median follow-up
HER2-negative first-line metastatic gastroesophageal adenocarcinomasource ↗
▲Dose Finding UpdateGivastomigTrial
Selection of 8 mg/kg dose for registrational development
HER2-negative first-line metastatic gastroesophageal adenocarcinomasource ↗
▲Partnership / LicenseYOL104Corporate
Visara enters exclusive option agreement with YOLO Immune to acquire worldwide rights to YOL104 Program and develop/commercialize YOL104-2 for OSSN
Ocular Surface Squamous Neoplasia (OSSN)source ↗
▲Partnership / LicenseHT006Corporate
Hiteck licenses ex-Greater China rights to HT006.2.2 to Visara
neurotrophic keratitissource ↗
▲Partnership / LicenseVIS-102Corporate
Visara licenses exclusive worldwide (ex-Greater China) rights to VIS-102 (HT006.2.2) from Wuhan Hiteck
neurotrophic keratitissource ↗
▲Fast Track DesignationGivastomigDesignation
FDA granted Fast Track Designation for givastomig in combination with nivolumab and chemotherapy for previously untreated HER2-negative advanced or metastatic GEA
first-line HER2-negative metastatic gastric cancersource ↗
◆Oral PresentationPresentation
NovaBridge to present at 2026 Jefferies Global Healthcare Conference
▲Fast Track DesignationGivastomigDesignation
FDA granted Fast Track Designation
previously untreated HER2-negative advanced or metastatic GEA in combination with nivolumab and chemotherapysource ↗
◆Oral PresentationPresentation
NovaBridge to present at H.C. Wainwright 4th Annual BioConnect Investor Conference
▲Topline ReadoutGivastomigClinical Data
Positive topline results from Phase 1b study of givastomig in first line gastric cancer
first line gastric cancersource ↗
▲Management ChangeCorporate
Appointment of Mark Hagler as President and Chief Commercial Officer
▲Type B MeetingGivastomigFDA Meeting
Productive FDA Type B meeting on accelerated approval pathway for givastomig in 1L Her2-, CLDN18.2+, PD-L1+ GEC
gastric cancersource ↗
▲Accelerated Approval PathwayGivastomigDesignation
FDA confirmed givastomig's potential eligibility for accelerated approval pathway
gastric cancersource ↗
◆Oral PresentationPresentation
NovaBridge to present at Leerink Partners 2026 Global Healthcare Conference
◆Oral PresentationVIS-101Presentation
Business update call to review Phase 2a data for VIS-101 in wet AMD
wet age-related macular degenerationsource ↗
▲Topline ReadoutVIS-101Clinical Data
Positive topline results from Phase 2a study of VIS-101 in wet AMD
wet age-related macular degenerationsource ↗
▲Type B MeetingGivastomigFDA Meeting
FDA Type B meeting confirmed potential eligibility for Accelerated Approval pathway for givastomig
gastric cancersource ↗
▲Accelerated Approval PathwayGivastomigDesignation
Potential eligibility for FDA Accelerated Approval Pathway reported
first-line HER2-negative, Claudin 18.2-positive, PD-L1-positive patients with gastroesophageal adenocarcinomasource ↗
▲Topline ReadoutVIS-101Clinical Data
Positive Phase 2a data reported
neovascular (wet) age-related macular degenerationsource ↗
▲First Patient DosedGivastomigTrial
First patient dosed in global Phase 2 randomized combination study of givastomig with nivolumab and chemotherapy
1L metastatic gastric cancersource ↗
●Trial InitiationGivastomigTrial
Global randomized Phase 2 study initiated
HER2-negative, 1L metastatic gastric cancersource ↗
▲Topline ReadoutGivastomigClinical Data
Positive givastomig dose expansion data from Phase 1b combination study in 1L metastatic gastric cancer
first line metastatic gastric cancersource ↗
▲Quarterly UpdateCorporate
Executive Chairman Fu Wei intends to purchase up to $5,000,000 of ADSs in open market transactions
▲Oral PresentationGivastomigPresentation
Positive dose expansion data presented from Phase 1b combination study
1L metastatic gastric cancersource ↗
▲Topline ReadoutGivastomigClinical Data
Positive Phase 1b dose expansion combination study data reported
first-line gastric cancersource ↗
◆Oral PresentationGivastomigPresentation
Phase 1b dose expansion data presentation in combination with nivolumab + chemo
1L gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinomasource ↗
◆Trial InitiationGivastomigTrial
First patient enrollment targeted for global randomized Phase 2 study of givastomig
gastric cancer and other Claudin 18.2-positive GI malignanciessource ↗
◆First Patient DosedGivastomigTrial
First patient enrollment in global randomized Phase 2 study of givastomig
Claudin 18.2-positive gastric cancer and other gastrointestinal malignanciessource ↗
▲End Of Phase 2 MeetingGivastomigFDA Meeting
Alignment with FDA on global registrational Phase 3 study protocol
HER2-negative first-line metastatic gastroesophageal adenocarcinomasource ↗
◆Poster PresentationragistomigPresentation
Poster presentation of expanded Phase 1 data for ragistomig at ESMO-IO 2025
solid tumorssource ↗
●Quarterly UpdateCorporate
Corporate name change from I-Mab to NovaBridge Biosciences and ticker change to NBP
▲Partnership / LicenseVIS-101Corporate
Visara assigns exclusive license for VIS-101 to Everest Medicines in Greater China and certain Asian countries
wet AMD, DME, RVOsource ↗
▲Full ResultsGivastomigClinical Data
Updated Safety, Efficacy and Biomarker Analysis from Phase I Monotherapy Study of Givastomig
Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)source ↗
◆Enrollment UpdateGivastomigTrial
Combination dose expansion (Givastomig + Nivolumab + mFOLFOX) ongoing; 8 mg/kg (n=20) and 12 mg/kg (n=20) enrolled
1L HER2(-) CLDN18.2+ unresectable or metastatic GC/GEJ/EACsource ↗
▲Oral PresentationGivastomigPresentation
Updated Phase 1 givastomig monotherapy data presented at AACR-NCI-EORTC Triple Meeting
gastroesophageal carcinomasource ↗
Past FDA Catalysts and PDUFA Decisions
How NBP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-25 | givastomig (TJ033721 / ABL111) | Phase 1b data presentation | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
6
Drugs Scored
rNPV / MCap
Top Drug
Top 30%
Micro Cap(rank 201 of 667)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Givastomig BiologicsNCT04900818 | Solid Tumor | Phase 2 | RECRUITING | 510 | Dec 1, 2027 | ||||||
| TJ003234 Small MoleculesCompletedNCT04341116 | Coronavirus Disease 2019 COVID-19 | Phase 2/3 | COMPLETED | 149 | Feb 7, 2022 | ||||||
| VIS-101 BiologicsCompletedNCT05456828 | Neovascular Age-related Macular Degeneration | Phase 1/2 | COMPLETED | 300 | Nov 3, 2025 | ||||||
| VIS-101 BiologicsCompletedNCT05940428 | Diabetic Macular Edema | Phase 1 | COMPLETED | 10 | Oct 21, 2024 | ||||||
| Uliledlimab BiologicsCompletedNCT05001347 | Ovarian Cancer | Phase 2 | COMPLETED | 25 | Feb 8, 2023 | ||||||
| TJ210001 Small MoleculesCompletedNCT04678921 | Solid Tumor | Phase 1 | COMPLETED | 16 | Nov 21, 2022 | ||||||
| TJ011133 Small MoleculesCompletedNCT03934814 | Solid Tumor | Phase 1 | COMPLETED | 98 | Jan 10, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every NBP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| givastomig Fast TrackAcceleratedOrphan | HER2-negative first-line metastatic gastroesophageal adenocarcinoma | Phase 1b | 2026-10-25 | objective response rate: 79% (23/29); disease control rate: 97% (28/29); median duration of response: 15.2 months; median progression free survival: 16.9 months; median follow up: 17.8 monthsRead More | NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational DevelopmentRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Woo Ian YingDirector | Option | 13,271 13,271 held | $0.00 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NBP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NBP for Q2 2026. | ||||
Ownership Trends
NBP Short Interest
Shares sold short, counted twice a month.
3.65%
Short % of Float
of tradable shares sold short
3.6M
Shares Sold Short
-3.3% vs prior count
6.9 High
Days to Cover
trading days of normal volume to buy every short share back
519.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NBP ranks across every disease it competes in
Competitive Position is a premium feature
See how NBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNBP News
NBP▼ -3.6%today
NovaBridge Biosciences to Participate in Upcoming Investor Conferences
NovaBridge Biosciences will participate in two investor conferences. CEO Srishti Gupta will present at the Jefferies Global Healthcare Conference alongside Jeffrey Nau from Visara. Additionally, Dr. Gupta will join CFO Chuck Silberstein for a fireside chat at the Evercore Healthcare Conference. Webcasts will be available for 90 days post-event.
Read more →NBPNovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
NovaBridge Biosciences appointed Chuck Silberstein as Chief Financial Officer, effective November 2, 2026. He succeeds Kyler Lei and brings over 25 years of experience in biotechnology and finance. Dr. Silberstein aims to enhance capital allocation and strategic opportunities as the company advances its clinical development programs.
Read more →NBP▼ -11.3%on this newsshared move
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
NovaBridge Biosciences presented updated Phase 1b data for givastomig at ESMO 2026. The results showed a 79% objective response rate and a 97% disease control rate among patients treated with the 8 mg/kg dose. The company plans to advance givastomig towards registrational development, supported by FDA interactions and designations. A webcast is scheduled for November 2, 2026, to discuss these findings.
Read more →NBP▲ +9.6%on this news
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Visara, a subsidiary of NovaBridge Biosciences, has entered an asset purchase option agreement with YOLO Immune for YOL104-2, a potential first-in-class therapy for ocular surface squamous neoplasia (OSSN). This agreement allows Visara to evaluate the program further while maintaining flexibility in capital allocation. YOL104-2 represents a significant opportunity in an area with unmet medical needs.
Read more →NBPHiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck has licensed its investigational eye drop HT006.2.2 to Visara for the treatment of neurotrophic keratitis, excluding Greater China. The drug has shown promising results in Phase 1b trials, with 50% of patients achieving complete corneal healing. Hiteck will receive upfront and milestone payments, while retaining rights in Greater China.
Read more →NBPVisara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
Visara has secured exclusive worldwide rights to develop VIS-102, an investigational nerve growth factor therapy for neurotrophic keratitis, from Wuhan Hiteck Biological Pharma. This therapy aims to improve corneal health with a more convenient treatment option. Early clinical data shows promising results, with a significant percentage of patients achieving complete corneal healing.
Read more →NBPNovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
NovaBridge Biosciences announced that updated results from the Phase 1b study of givastomig will be presented at the ESMO Congress 2026. The study focuses on the safety and efficacy of givastomig in combination with nivolumab and chemotherapy for treating metastatic gastroesophageal adenocarcinoma. The findings aim to strengthen the drug's development as a first-line treatment option.
Read more →NBPNovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
NovaBridge Biosciences has appointed Martin Dewhurst as an independent director on its Board. With over 30 years of experience in healthcare leadership, Dewhurst will also serve on the Audit and Compensation Committees. His expertise is expected to support the company's growth and governance. This appointment follows the departure of Liu Xin from the Board.
Read more →NBPNovaBridge Biosciences to Participate in September Investor Conferences
NovaBridge Biosciences will participate in two investor conferences in September 2026, highlighting its commitment to engaging with investors. CEO Srishti Gupta will present at both the Cantor 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company aims to advance its therapeutic programs in oncology and ophthalmology.
Read more →NBPNovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
NovaBridge Biosciences reported its financial results for the first half of 2026, highlighting significant progress in its clinical pipeline, particularly with givastomig and VIS-101. The company aims to initiate a Phase 3 study for givastomig by the end of 2026 and is advancing VIS-101 towards Phase 2b. Despite a net loss of $37.9 million, NovaBridge maintains a strong cash position to support its strategic goals.
Read more →NBPNovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
NovaBridge Biosciences will hold a webcast on August 20, 2026, to discuss its financial results for the first half of the year and recent corporate developments. The company focuses on innovative therapies in oncology and ophthalmology, with programs like givastomig and VIS-101. The webcast will be accessible live and archived for later viewing.
Read more →NBPNovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
NovaBridge Biosciences has announced its annual general meeting (AGM) scheduled for September 8, 2026, in Shanghai. Shareholders of record by July 27, 2026, are entitled to attend and vote. The company has also filed its annual report with the SEC, detailing its financial performance and ongoing clinical developments.
Read more →NBP▲ +20.7%on this news
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO, effective July 1, 2026. Dr. Gupta, who has over two decades of leadership experience, aims to advance the company's drug candidates, including givastomig and VIS-101. She succeeds Xi-Yong Fu, who will remain in an advisory role during the transition.
Read more →NBPNovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
NovaBridge Biosciences has received FDA Fast Track Designation for its drug givastomig, aimed at treating first-line HER2-negative metastatic gastric cancer. The designation is based on positive Phase 1b trial results demonstrating efficacy and tolerability. The company plans to initiate a registrational Phase 3 trial as early as Q4 2026, with detailed data presentation expected in late 2026.
Read more →NBPNovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
NovaBridge Biosciences will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The company's presentation will include updates on its innovative pipeline, including givastomig and VIS-101. Givastomig is currently in a Phase 2 study for gastric cancer, while VIS-101 is expected to enter a Phase 2b study for retinal diseases. The webcast will be available for 90 days post-conference.
Read more →NBPNovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
NovaBridge Biosciences will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is advancing its innovative pipeline, including givastomig for gastric cancer and VIS-101 for retinal diseases. Positive results from previous studies bolster its prospects. The presentation will be available via webcast for 90 days.
Read more →NBPNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
NovaBridge Biosciences has appointed Mark Hagler as President and Chief Commercial Officer to enhance its commercial strategy. Hagler brings over 25 years of experience in biopharmaceuticals, particularly in oncology and ophthalmology. His leadership is expected to drive the advancement of NovaBridge's pipeline, including the potential first-in-class drug givastomig for gastric cancer.
Read more →NBPNovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
NovaBridge Biosciences reported its financial results for 2025, highlighting its transformation into a global biotech platform. The company has two lead programs, givastomig for gastric cancer and VIS-101 for wet AMD, both showing promising clinical data. Despite a significant net loss, NovaBridge maintains a strong cash position expected to support operations through 2028.
Read more →NBPNovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
NovaBridge announced a productive Type B meeting with the FDA, confirming the eligibility of its drug givastomig for an accelerated approval pathway in gastric cancer. The company intends to begin a Phase 3 trial combining givastomig with immunochemotherapy as early as Q4 2026, based on promising Phase 1b trial results showing a 75% objective response rate. Givastomig is being positioned as a first-in-class therapy for patients with specific tumor characteristics in gastroesophageal cancer. Detailed trial designs will be discussed in further meetings with the FDA.
Read more →NBPNovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
NovaBridge Biosciences and its subsidiary Visara have announced positive topline results from the Phase 2a study of VIS-101, a dual VEGF-A X ANG-2 inhibitor for wet AMD. The study showed rapid and durable treatment responses, with a favorable safety profile. Plans are underway to initiate a Phase 2b study later this year, followed by a global Phase 3 program in 2027.
Read more →About NovaBridge Biosciences
BIOPHARMAWATCH ELITE
Trade the next NBP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime